|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. For example, here is how to disable FireFox ad content blocking while on Silicon Investor.|
A NEW TEVA IS IN THE MAKING HERE FOLKS....PATIENCE IS ALL YOU NEED TO GET RICH WITH THIS ONE !!!! GLTA
This low float sleeping giant awaiting 6 FDA approvals .IPCI has 15 Drugs in Pipeline many nearing ANDA/NDA filing including a potential Blockbuster .
Burn-rate is only 1.5 M per Q means enuff till 2013 EXCLUDING upfront payments from Upcoming Partnerships . IPCI will be profitable in 2012 !!!
CEO is the largest Shareholder of this unknown Goldmine with over 6 M shares .First FDA approval and new Partnership is imminent ..
Market Cap: $ 47.7 M
Cash: $ 7.5 M
Shares Out: 15.9 Mil...(11 Mil Shares held by Insiders/Institutions)
Low Float: Only 3 M
New Article ( worth $15++ per share )
Upcoming Milestones 2011
Intellipharmaceutics now has six ANDAs being reviewed by the FDA for approval, with reported sales by others for branded and generic versions of these products being approximately $6.6 billion for the 12 months ended September 2011. The Company develops both ANDA product candidates and new drugs through the New Drug Application (NDA) 505(b)(2) regulatory pathway.
Ladenburg Thalmann has initiated coverage of Intellipharmaceutics International (NADAQ:IPCI; TSX:I) with a “buy” rating and price target of $7.
Analyst Kevin DeGeeter writes that Intellipharmaceutics’ “expertise in extended-release drug development offers a unique mix of multiple near-term revenue opportunities from the launch of extended-release generic drugs and significant longer-term upside potential from the development of proprietary controlled-release pain products.”
He cites four catalysts for the company over the next 12-to-18 months, including the launch of generic Focalin XR, with the company believed to be the first to file on at least one dose strength; completion of Phase 1 dosing of the extended-release oxycodone program; disclosure of a second proprietary extended-release program, which may be for a large unmet need such as morphine; and disclosure of two or more additional ANDA filings.
“We believe Toronto-based Intellipharmaceuticals has remained a relatively undiscovered story for most institutional investors since its 2009 merger with Vasogen, but expect the upcoming launch of Focalin XR (in the fourth quarter of 2012) to raise the company’s investor profile,” Mr. DeGeeter added.
|© 2019 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|